And they get a payment stream on sales that they are themselves not making now because their pricing strategy in developing countries is not one that makes it affordable for the vast majority of people who have to pay out of pocket for medicines. So those are unrealized sales for the brand-name companies now. If you create competition in those markets by allowing generics to get in there and compete with them and bring the prices down, they will be lining up customers that will be making sales to patients who were not getting medicines before and indeed paying royalties to the brand-name company on those contracts, which the law requires them to disclose.
The royalty scheme that's in the law now is based, actually, on a proposal that we put forward back in 2004, so that the poorer the country, the less developed the country, the lower the royalty payment should be. The maximum royalty that should ever be payable is 4% of the value of the contract. That was the standard that was used when we used to use compulsory licensing regularly in Canada to supply the Canadian market. So there's no reason that poorer countries should be paying anything near what we used to pay by way of a royalty when you're supplying a rich country market.